New hope for advanced breast cancer patients Who've run out of options
NCT ID NCT06081959
Summary
This study is testing whether a new drug called SKB264 works better than standard treatments for people with advanced HR+/HER2- breast cancer that has spread or returned after chemotherapy. Researchers will compare SKB264 against whatever treatment the doctor would normally choose, measuring how long patients live without their cancer getting worse and monitoring side effects. The study is open to adults with this specific type of breast cancer who have already tried at least one chemotherapy treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Science
RECRUITINGBeijing, Beijing Municipality, 100021, China
Contact
Conditions
Explore the condition pages connected to this study.